EODData

MEMBERSHIP REGISTER LOG IN

FRA, ON4: ONO PHARMACEUT.

13 Nov 2025
LAST:

10.90

CHANGE:
 0.00		OPEN:
11.00		HIGH:
11.00		ASK:
0.00		VOLUME:
315
CHG(%):
0.00		PREV:
10.90		LOW:
10.90		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
13 Nov 2511.0011.0010.9010.90315
12 Nov 2510.9010.9010.9010.9075
11 Nov 2510.7010.8010.5010.5075
10 Nov 2510.6010.6010.5010.6075
07 Nov 2511.1011.1010.6010.6075
06 Nov 2510.8010.8010.8010.80100
05 Nov 2510.6010.6010.6010.60100
04 Nov 2510.6010.7010.6010.70100
03 Nov 2510.5010.5010.5010.50100
31 Oct 2510.3010.6010.3010.40100

COMPANY PROFILE

Name:ONO PHARMACEUT.
About:Ono Pharmaceutical Co., Ltd. engages in production, purchase, and sale of pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. It also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, for the treatment of Secondary Hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.
Sector:Healthcare
Address:8-2, Kyutaromachi 1-chome, Osaka, Japan, 541-8564
Website:https://www.ono-pharma.com
ISIN:JP3197600004

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:18.28 
Forward P/E:13.50 
PEG Ratio:-0.32 
Price to Sales:0.01 
Price to Book:0.01 
Profit Margin:0.10 
Operating Margin:0.23 
Return on Assets:0.03 
Return on Equity:0.07 
DivYield:0.05 
Div/Share:80.00 
Revenue:2.836B 
EBITDA:515.5M 
Shares:469.77M 
Market Cap:5.121B 

TECHNICAL INDICATORS

MA5:10.701.9%
MA10:10.652.3%
MA20:10.424.6%
MA50:10.068.3%
MA100:9.7511.8%
MA200:9.7312.1%
STO9:66.67
STO14:84.00 
RSI14:67.31 
MTM14:0.60
ROC14:0.06 
ATR:0.26 
Week High:11.101.8%
Week Low:10.503.8%
Month High:11.101.8%
Month Low:9.7012.1%
Year High:11.273.4%
Year Low:8.9421.9%
Volatility:48.23 

RECENT DIVIDENDS

Date Amount
29 Sep 2025$0.23
28 Mar 2025$0.23
27 Sep 2024$0.23
28 Mar 2024$0.23
28 Sep 2023$0.23
30 Mar 2023$0.21
29 Sep 2022$0.19
30 Mar 2022$0.16